Non-Exclusive Drug Discount Agreement for Miglustat
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Miglustat (ATC-Code nach WHO: A16AX06)
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
25 / 100
Risk factors
No guaranteed demand; actual purchases depend on prescription behavior and pharmacy stocking.
Inconsistency in structured data: electronicSubmission marked 'not-allowed' but notice requires electronic submission v...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- May 31, 2027
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until May 2027
- Supply of Miglustat (ATC A16AX06) pharmaceutical products
- Non-exclusive discount agreement under §130a(8) SGB V
Show full summary
Non-exclusive drug discount agreement for Miglustat (ATC A16AX06) via an open-house model under §130a(8) SGB V. Open to all eligible pharmaceutical companies; no exclusivity, no guaranteed volumes. Contract runs until 31 May 2027. First submission deadline: 5 May 2025; further deadlines apply. Estimated value not disclosed.
Risks
No guaranteed demand; actual purchases depend on prescription behavior and pharmacy stocking.
Inconsistency in structured data: electronicSubmission marked 'not-allowed' but notice requires electronic submission v...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical company within the meaning of §4(18) AMG
- Must not be subject to Russian sanctions under EU Regulation 833/2014
Administrative
- Submission via DTVP electronic portal after access request
Requirements may be incomplete.
Buyer
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Non-Exclusive Drug Discount Agreement for Miglustat
Open-house model for Miglustat-based pharmaceuticals; no exclusivity, no minimum quantities, non-negotiable terms.
Location
Duration
Category
Deadline
Award details
Siehe Kurzbeschreibung
Value note
Show original TED data
Original lot title
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Miglustat (ATC-Code nach WHO: A16AX06)
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 10 Apr 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 238740-2025
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
25 / 100
Risk factors
No guaranteed demand; actual purchases depend on prescription behavior and pharmacy stocking.
Inconsistency in structured data: electronicSubmission marked 'not-allowed' but notice requires electronic submission v...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications